Get the Stockscreener App
436.95
0.15%
0.67
Pre-market:
432.00
-4.95
-1.13%
Madrigal Pharmaceuticals Inc stock is traded at $436.95, with a volume of 176.60K.
It is up +0.15% in the last 24 hours and down -3.71% over the past month.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.
See More
Previous Close:
$436.28
Open:
$444.09
24h Volume:
176.60K
Relative Volume:
0.47
Market Cap:
$9.70B
Revenue:
-
Net Income/Loss:
$-518.67M
P/E Ratio:
-17.39
EPS:
-25.12
Net Cash Flow:
$-438.32M
1W Performance:
-2.71%
1M Performance:
-3.71%
6M Performance:
+44.31%
1Y Performance:
+101.57%
1-Day Range:
$435.21
$444.09
1-Week Range:
$433.00
$462.88
52-Week Range:
$200.63
$463.62
Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile
Name
Madrigal Pharmaceuticals Inc
Sector
Industry
Phone
404-380-9263
Address
200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA
Compare MDGL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MDGL
Madrigal Pharmaceuticals Inc
|
436.95 | 9.72B | 0 | -518.67M | -438.32M | -25.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.15 | 105.19B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
450.68 | 60.24B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.86 | 61.82B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
798.94 | 49.09B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
351.09 | 37.52B | 4.56B | -176.77M | 225.30M | -1.7177 |
Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-04-25 | Resumed | H.C. Wainwright | Buy |
| Feb-28-25 | Upgrade | B. Riley Securities | Neutral → Buy |
| Feb-27-25 | Reiterated | H.C. Wainwright | Buy |
| Jun-28-24 | Initiated | Cantor Fitzgerald | Neutral |
| Jun-11-24 | Initiated | Wolfe Research | Outperform |
| Apr-22-24 | Initiated | BofA Securities | Underperform |
| Mar-15-24 | Upgrade | B. Riley Securities | Sell → Neutral |
| Mar-06-24 | Initiated | Citigroup | Buy |
| Feb-26-24 | Downgrade | B. Riley Securities | Neutral → Sell |
| Dec-20-22 | Reiterated | Oppenheimer | Outperform |
| Dec-19-22 | Reiterated | H.C. Wainwright | Buy |
| Dec-19-22 | Reiterated | Piper Sandler | Overweight |
| Dec-19-22 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Jul-08-22 | Downgrade | B. Riley Securities | Buy → Neutral |
| Oct-07-21 | Initiated | Jefferies | Buy |
| Aug-06-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| May-20-21 | Resumed | Goldman | Buy |
| Nov-24-20 | Resumed | Evercore ISI | Outperform |
| Nov-06-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-31-20 | Initiated | Piper Sandler | Overweight |
| Jun-05-20 | Initiated | BMO Capital Markets | Market Perform |
| May-05-20 | Initiated | Chardan Capital Markets | Buy |
| Jan-30-20 | Initiated | Canaccord Genuity | Buy |
| Jan-09-20 | Upgrade | UBS | Neutral → Buy |
| Nov-07-19 | Reiterated | H.C. Wainwright | Buy |
| Jun-25-19 | Initiated | Stifel | Hold |
| Jun-10-19 | Upgrade | B. Riley FBR | Neutral → Buy |
| Feb-28-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-22-19 | Initiated | SVB Leerink | Outperform |
| Jan-23-19 | Initiated | UBS | Neutral |
| Dec-14-18 | Initiated | Wolfe Research | Outperform |
| Dec-12-18 | Initiated | B. Riley FBR | Neutral |
| Nov-19-18 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Nov-16-18 | Upgrade | Evercore ISI | In-line → Outperform |
| Sep-04-18 | Initiated | Citigroup | Buy |
| Aug-06-18 | Downgrade | Goldman | Buy → Neutral |
| Jun-28-18 | Initiated | Raymond James | Mkt Perform |
View All
Madrigal Pharmaceuticals Inc Stock (MDGL) Latest News
Madrigal Pharmaceuticals Inc. stock daily chart insights2025 Top Decliners & Technical Entry and Exit Alerts - newser.com
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Knights of Columbus Asset Advisors LLC Increases Stock Position in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
How strong is Madrigal Pharmaceuticals Inc. (YDO1) stock earnings growthTrade Analysis Report & Fast Moving Stock Trade Plans - newser.com
Short interest data insights for Madrigal Pharmaceuticals Inc.Quarterly Profit Summary & AI Enhanced Trading Signals - newser.com
Will Madrigal Pharmaceuticals Inc. (YDO1) stock keep high P E multiplesJuly 2025 Rallies & Long-Term Investment Growth Plans - newser.com
What analysts say about Madrigal Pharmaceuticals Inc YDO1 stockMarket Sentiment Shifts & Breakout Stock Alerts - earlytimes.in
Strid Group LLC Buys Shares of 2,500 Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Published on: 2025-10-05 03:01:06 - newser.com
J. Safra Sarasin Holding AG Increases Holdings in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Madrigal Pharmaceuticals Hits New 52-Week High of $463.48 - Markets Mojo
Signal strength of Madrigal Pharmaceuticals Inc. stock in tech scannersJuly 2025 Opening Moves & Low Risk Investment Opportunities - newser.com
Q3 Earnings Estimate for MDGL Issued By B. Riley - Defense World
How to use Fibonacci retracement on Madrigal Pharmaceuticals Inc.Earnings Overview Report & Technical Pattern Based Signals - newser.com
What is B. Riley's Forecast for MDGL Q3 Earnings? - MarketBeat
Madrigal Pharmaceuticals, Inc. $MDGL Holdings Decreased by AMI Asset Management Corp - MarketBeat
Madrigal Pharmaceuticals to Present at 43rd Annual J.P. Morgan Healthcare Conference - MSN
Madrigal Pharmaceuticals Achieves 114.43% Annual Growth, Marking It as a Multibagger Stock - Markets Mojo
Madrigal Pharmaceuticals Hits Day High with 8.43% Surge in Stock Price - Markets Mojo
Madrigal Pharmaceuticals Hits New 52-Week High of $460.00 - Markets Mojo
What drives Madrigal Pharmaceuticals Inc YDO1 stock priceSupport Zone Identification & Low Risk High Yield - earlytimes.in
Can Prince Pipes and Fittings Limited Reach New Highs in YEAR Resistance Levels ReviewedBreakout Stock Watch & Rapid Profit Growth - earlytimes.in
Madrigal Pharmaceuticals (NASDAQ:MDGL) Reaches New 52-Week High on Analyst Upgrade - Defense World
Madrigal Pharmaceuticals (NASDAQ:MDGL) Hits New 52-Week High After Analyst Upgrade - MarketBeat
Madrigal Pharmaceuticals stock hits all-time high at 457.47 USD By Investing.com - Investing.com Australia
Madrigal Pharmaceuticals stock hits all-time high at 457.47 USD - Investing.com India
Madrigal Pharmaceuticals Advances NASH Treatment with Full Enrollment of MAESTRO-NASH OUTCOMES Trial - MSN
Madrigal Pharmaceuticals: Rezdiffra's US And EU Rollout Remains Promising (NASDAQ:MDGL) - Seeking Alpha
Evaluating Madrigal Pharmaceuticals Inc. with trendline analysisEntry Point & Free Community Consensus Stock Picks - newser.com
B. Riley Issues Positive Forecast for Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock Price - Defense World
Published on: 2025-09-29 16:45:10 - newser.com
A Glimpse Into The Expert Outlook On Madrigal Pharmaceuticals Through 7 Analysts - Benzinga
MSN - MSN
MDGL: B. Riley Securities Raises Price Target to $560 | MDGL Sto - GuruFocus
B. Riley Raises Price Target on Madrigal Pharmaceuticals to $560 From $460, Keeps Buy Rating - MarketScreener
Madrigal Pharmaceuticals, Inc. (MDGL) Stock Analysis: Exploring Growth Potential Amid 1,353.80% Revenue Surge - DirectorsTalk Interviews
Madrigal Pharmaceuticals, Inc. (MDGL) Stock Analysis: Unveiling a 13.58% Potential Upside with Robust Revenue Growth - DirectorsTalk Interviews
Published on: 2025-09-28 23:27:34 - newser.com
What drives Madrigal Pharmaceuticals Inc stock priceSupport and Resistance Levels & Rapid Capital Trading - Early Times
Is Madrigal Pharmaceuticals Inc a good long term investmentAI-Driven Market Analysis & Big Profit Low Investment - earlytimes.in
Published on: 2025-09-28 01:35:26 - newser.com
Madrigal Pharmaceuticals Announces Positive Quality of Life Outcomes for Rezdiffra in NASH Treatment - MSN
What analysts say about Madrigal Pharmaceuticals Inc stockSupport Zone Identification & Unlock Long-Term Capital Growth Ideas - Early Times
Madrigal Pharmaceuticals Inc Stock Analysis and ForecastAutomated Trading Signals & Low Entry Capital Stocks - Early Times
Madrigal Pharmaceuticals Inc Stock (MDGL) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.05%
4.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):